Araştırma Makalesi

Could sP-Selectin and sICAM-1 be potential biomarkers in status epilepticus?

Cilt: 6 Sayı: 3 30 Mart 2019
PDF İndir
EN

Could sP-Selectin and sICAM-1 be potential biomarkers in status epilepticus?

Abstract

Objective: To investigate whether soluble P-selectin (sP-selectin) and soluble intercellular adhesion molecule-1 (sICAM-1) might be potential biomarkers that predict the course and prognosis of status epilepticus (SE).

Patients and Methods: Fourty-two adult patients with SE between February 2012 and December 2013 were included in the study. Clinical and demographic features of the patients were recorded and surviving patients were followed for 13.6 ± 4.6 months. Serum sICAM-1 and sP-selectin levels were measured during SE or within 24 hours of SE, and compared with 28 subjects in the control group.

Results: Levels of serum sP-selectin and sICAM-1 were higher in the SE group compared with the control group (P: 0.04 and P: 0.02, respectively). It was shown that higher levels of serum sICAM-1 correlated with poor outcomes (P: 0.017) and “ROC curve” analysis showed that levels higher than 457 ng/mL predicted poor outcomes with 71% sensitivity and 68% specificity. Levels of serum sP-selectin did not correlate with outcomes. Subgroup analyses revealed levels of serum sICAM-1 were significantly higher in the epilepsia partialis continua (EPC) group compared with the control group (P: 0.012) and levels of serum sP-selectin were not different between subgroups and controls. Levels of serum sP-selectin and sICAM-1 didn’t differ between subgroups of SE and different etiologies. 

Conclusion: Higher levels of serum sICAM-1 may predict poor outcome in SE, as a result sICAM-1 may be used as a biomarker of the prognosis of SE in clinical practice. The production of sICAM-1 may increase particularly in EPC. However, no correlation was found between etiology of SE and serum level of sICAM-1, even in patients with EPC. Serum level of sP-Selectin is not an appropriate biomarker for the prognosis of SE. Serum levels of sICAM-1 and sP-selectin are not appropriate biomarkers of refractory SE.

Keywords

Kaynakça

  1. 1. Engel, J., Jr., Pitkanen, A., Loeb, J.A., Dudek, F.E., Bertram, E.H., 3rd, Cole, A.J., Moshe, S.L., Wiebe, S., Jensen, F.E., Mody, I., Nehlig, A. and Vezzani, A. Epilepsy biomarkers. Epilepsia 2013; 54 Suppl 4:61-69.
  2. 2. Wasterlain, C.G., Fujikawa, D.G., Penix, L. and Sankar, R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993; 34 Suppl 1:S37-53.
  3. 3. Toro, C.T., Hallak, J.E., Dunham, J.S., Leite, J.P., Sakamoto, A.C., Guarnieri, R., Fong, V. and Deakin, J.F. The NR1 N-methyl-D-aspartate subunit and brain-derived neurotrophic factor in temporal lobe epilepsy hippocampus: a comparison of patients with and without coexisting psychiatric symptoms. Epilepsia 2007; 48:2352-2356.
  4. 4. Lamers, K.J., Vos, P., Verbeek, M.M., Rosmalen, F., van Geel, W.J. and van Engelen, B.G. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res Bull 2003; 61:261-264.
  5. 5. Gurnett, C.A., Landt, M. and Wong, M. Analysis of cerebrospinal fluid glial fibrillary acidic protein after seizures in children. Epilepsia 2003; 44:1455-1458.
  6. 6. Rejdak, K., Kuhle, J., Ruegg, S., Lindberg, R.L., Petzold, A., Sulejczak, D., Papuc, E., Rejdak, R., Stelmasiak, Z. and Grieb, P. Neurofilament heavy chain and heat shock protein 70 as markers of seizure-related brain injury. Epilepsia 2012; 53:922-927.
  7. 7. Royds, J.A., Davies-Jones, G.A., Lewtas, N.A., Timperley, W.R. and Taylor, C.B. Enolase isoenzymes in the cerebrospinal fluid of patients with diseases of the nervous system. J Neurol Neurosurg Psychiatry 1983; 46:1031-1036.
  8. 8. Quirico-Santos, T., Nascimento Mello, A., Casimiro Gomes, A., de Carvalho, L.P., de Souza, J.M. and Alves-Leon, S. Increased metalloprotease activity in the epileptogenic lesion--Lobectomy reduces metalloprotease activity and urokinase-type uPAR circulating levels. Brain Res 2013; 1538:172-181.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Aysegul Telci Bu kişi benim
Türkiye

Ahmet Dirican Bu kişi benim
Türkiye

Candan Gurses Bu kişi benim
Türkiye

Yayımlanma Tarihi

30 Mart 2019

Gönderilme Tarihi

30 Aralık 2018

Kabul Tarihi

6 Mart 2019

Yayımlandığı Sayı

Yıl 2019 Cilt: 6 Sayı: 3

Kaynak Göster

APA
Atmaca, M. M., Telci, A., Dirican, A., & Gurses, C. (2019). Could sP-Selectin and sICAM-1 be potential biomarkers in status epilepticus? Medical Science and Discovery, 6(3), 32-40. https://doi.org/10.17546/msd.505192
AMA
1.Atmaca MM, Telci A, Dirican A, Gurses C. Could sP-Selectin and sICAM-1 be potential biomarkers in status epilepticus? Med Sci Discov. 2019;6(3):32-40. doi:10.17546/msd.505192
Chicago
Atmaca, Murat Mert, Aysegul Telci, Ahmet Dirican, ve Candan Gurses. 2019. “Could sP-Selectin and sICAM-1 be potential biomarkers in status epilepticus?”. Medical Science and Discovery 6 (3): 32-40. https://doi.org/10.17546/msd.505192.
EndNote
Atmaca MM, Telci A, Dirican A, Gurses C (01 Mart 2019) Could sP-Selectin and sICAM-1 be potential biomarkers in status epilepticus? Medical Science and Discovery 6 3 32–40.
IEEE
[1]M. M. Atmaca, A. Telci, A. Dirican, ve C. Gurses, “Could sP-Selectin and sICAM-1 be potential biomarkers in status epilepticus?”, Med Sci Discov, c. 6, sy 3, ss. 32–40, Mar. 2019, doi: 10.17546/msd.505192.
ISNAD
Atmaca, Murat Mert - Telci, Aysegul - Dirican, Ahmet - Gurses, Candan. “Could sP-Selectin and sICAM-1 be potential biomarkers in status epilepticus?”. Medical Science and Discovery 6/3 (01 Mart 2019): 32-40. https://doi.org/10.17546/msd.505192.
JAMA
1.Atmaca MM, Telci A, Dirican A, Gurses C. Could sP-Selectin and sICAM-1 be potential biomarkers in status epilepticus? Med Sci Discov. 2019;6:32–40.
MLA
Atmaca, Murat Mert, vd. “Could sP-Selectin and sICAM-1 be potential biomarkers in status epilepticus?”. Medical Science and Discovery, c. 6, sy 3, Mart 2019, ss. 32-40, doi:10.17546/msd.505192.
Vancouver
1.Murat Mert Atmaca, Aysegul Telci, Ahmet Dirican, Candan Gurses. Could sP-Selectin and sICAM-1 be potential biomarkers in status epilepticus? Med Sci Discov. 01 Mart 2019;6(3):32-40. doi:10.17546/msd.505192